DA
THRX

Denali Advisors’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Denali Advisors’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-103,800
Closed -$420K – 514
2023
Q4 		$420K Sell
103,800
-24,100
-19% -$73.5K 0.13% 165
2023
Q3 		$344K Buy
127,900
+111,400
+675% +$437K 0.12% 176
2023
Q2 		$154K Buy
+16,500
New +$163K 0.05% 238

Denali Advisors's THRX Position: Q1 2024 in Review

Denali Advisors sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 103,800 shares — an estimated $420K sold.

Denali Advisors first reported a position in THRX in Q2 2023 and held it in 3 quarters. The position peaked at $420K in Q4 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

  • Denali Advisors reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Denali Advisors sold 103,800 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $420K.
  • Denali Advisors first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 3 quarters.
  • Denali Advisors's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $420K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Denali Advisors's 13F filing for Q1 2024, filed 19 Apr 2024.